- Home
- FGEN vs BOLD Comparison
FGEN vs BOLD Comparison
Compare FGEN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- BOLD
- Stock Information
- Founded
- FGEN 1993
- BOLD 2018
- Country
- FGEN United States
- BOLD United States
- Employees
- FGEN N/A
- BOLD N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- FGEN Health Care
- BOLD
- Exchange
- FGEN Nasdaq
- BOLD Nasdaq
- Market Cap
- FGEN 33.5M
- BOLD 30.3M
- IPO Year
- FGEN 2014
- BOLD 2024
- Fundamental
- Price
- FGEN $5.37
- BOLD $1.09
- Analyst Decision
- FGEN Strong Buy
- BOLD Buy
- Analyst Count
- FGEN 1
- BOLD 3
- Target Price
- FGEN $250.00
- BOLD $4.00
- AVG Volume (30 Days)
- FGEN 60.6K
- BOLD 367.5K
- Earning Date
- FGEN 08-05-2025
- BOLD 08-11-2025
- Dividend Yield
- FGEN N/A
- BOLD N/A
- EPS Growth
- FGEN N/A
- BOLD N/A
- EPS
- FGEN N/A
- BOLD N/A
- Revenue
- FGEN $6,996,000.00
- BOLD N/A
- Revenue This Year
- FGEN N/A
- BOLD N/A
- Revenue Next Year
- FGEN N/A
- BOLD N/A
- P/E Ratio
- FGEN N/A
- BOLD N/A
- Revenue Growth
- FGEN N/A
- BOLD N/A
- 52 Week Low
- FGEN $4.50
- BOLD $1.00
- 52 Week High
- FGEN $38.25
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- FGEN 36.45
- BOLD N/A
- Support Level
- FGEN $4.85
- BOLD N/A
- Resistance Level
- FGEN $5.73
- BOLD N/A
- Average True Range (ATR)
- FGEN 0.51
- BOLD 0.00
- MACD
- FGEN -0.00
- BOLD 0.00
- Stochastic Oscillator
- FGEN 24.19
- BOLD 0.00
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.